MRVI Q3 2025 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M-36.2% YoY

Gross Profit

$6M13.6% margin

Operating Income

$115M277.3% margin

Net Income

-$26M-61.4% margin

EPS (Diluted)

$-0.18

QoQ Revenue Growth

-12.2%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$18M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$849M

Total Liabilities

$417M

Stockholders' Equity

$245M

Cash & Equivalents

$244M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$65M	-36.2%
Gross Profit	$6M	$28M	-80.1%
Operating Income	$115M	-$169M	+168.3%
Net Income	-$26M	-$99M	+74.2%

Revenue Segments

Nucleic Acid Production Segment

$25M61%

Biologics Safety Testing Segment

$16M39%

Geographic Segments

North America

$25M60%

Asia Pacific

$8M20%

EMEA

$8M19%

Latin And Central America

$296,0001%